BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 30593567)

  • 1. Different roles of E proteins in t(8;21) leukemia: E2-2 compromises the function of AETFC and negatively regulates leukemogenesis.
    Liu N; Song J; Xie Y; Wang XL; Rong B; Man N; Zhang MM; Zhang Q; Gao FF; Du MR; Zhang Y; Shen J; Xu CH; Hu CL; Wu JC; Liu P; Zhang YL; Xie YY; Liu P; Huang JY; Huang QH; Lan F; Shen S; Nimer SD; Chen Z; Chen SJ; Roeder RG; Wang L; Sun XJ
    Proc Natl Acad Sci U S A; 2019 Jan; 116(3):890-899. PubMed ID: 30593567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis.
    Sun XJ; Wang Z; Wang L; Jiang Y; Kost N; Soong TD; Chen WY; Tang Z; Nakadai T; Elemento O; Fischle W; Melnick A; Patel DJ; Nimer SD; Roeder RG
    Nature; 2013 Aug; 500(7460):93-7. PubMed ID: 23812588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LYL1 facilitates AETFC assembly and gene activation by recruiting CARM1 in t(8;21) AML.
    Chen Q; Cevher MA; Jiang Q; Wang S; Sun X; Roeder RG; Chen M
    Proc Natl Acad Sci U S A; 2022 Oct; 119(42):e2213718119. PubMed ID: 36215477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure of the AML1-ETO eTAFH domain-HEB peptide complex and its contribution to AML1-ETO activity.
    Park S; Chen W; Cierpicki T; Tonelli M; Cai X; Speck NA; Bushweller JH
    Blood; 2009 Apr; 113(15):3558-67. PubMed ID: 19204326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic silencing of miR564 contributes to the leukemogenesis of t(8;21) acute myeloid leukemia.
    Yang E; Guan W; Gong D; Gao X; Han C; Zhang J; Wang H; Wang M; Li Y; Yu L
    Clin Sci (Lond); 2020 Dec; 134(23):3079-3091. PubMed ID: 33201243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An AML1-ETO/miR-29b-1 regulatory circuit modulates phenotypic properties of acute myeloid leukemia cells.
    Zaidi SK; Perez AW; White ES; Lian JB; Stein JL; Stein GS
    Oncotarget; 2017 Jun; 8(25):39994-40005. PubMed ID: 28611288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. YTHDF2 is a potential target of AML1/ETO-HIF1α loop-mediated cell proliferation in t(8;21) AML.
    Chen Z; Shao YL; Wang LL; Lin J; Zhang JB; Ding Y; Gao BB; Liu DH; Gao XN
    Oncogene; 2021 Jun; 40(22):3786-3798. PubMed ID: 33958724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AML1/ETO oncoprotein is directed to AML1 binding regions and co-localizes with AML1 and HEB on its targets.
    Gardini A; Cesaroni M; Luzi L; Okumura AJ; Biggs JR; Minardi SP; Venturini E; Zhang DE; Pelicci PG; Alcalay M
    PLoS Genet; 2008 Nov; 4(11):e1000275. PubMed ID: 19043539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.
    Vangala RK; Heiss-Neumann MS; Rangatia JS; Singh SM; Schoch C; Tenen DG; Hiddemann W; Behre G
    Blood; 2003 Jan; 101(1):270-7. PubMed ID: 12393465
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Hematopoietic Transcription Factors RUNX1 and ERG Prevent AML1-ETO Oncogene Overexpression and Onset of the Apoptosis Program in t(8;21) AMLs.
    Mandoli A; Singh AA; Prange KHM; Tijchon E; Oerlemans M; Dirks R; Ter Huurne M; Wierenga ATJ; Janssen-Megens EM; Berentsen K; Sharifi N; Kim B; Matarese F; Nguyen LN; Hubner NC; Rao NA; van den Akker E; Altucci L; Vellenga E; Stunnenberg HG; Martens JHA
    Cell Rep; 2016 Nov; 17(8):2087-2100. PubMed ID: 27851970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing of microRNA-193a contributes to leukemogenesis in t(8;21) acute myeloid leukemia by activating the PTEN/PI3K signal pathway.
    Li Y; Gao L; Luo X; Wang L; Gao X; Wang W; Sun J; Dou L; Li J; Xu C; Wang L; Zhou M; Jiang M; Zhou J; Caligiuri MA; Nervi C; Bloomfield CD; Marcucci G; Yu L
    Blood; 2013 Jan; 121(3):499-509. PubMed ID: 23223432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AML1/ETO trans-activates c-KIT expression through the long range interaction between promoter and intronic enhancer.
    Tian Y; Wang G; Hu Q; Xiao X; Chen S
    J Cell Biochem; 2018 Apr; 119(4):3706-3715. PubMed ID: 29236325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.
    Thiel VN; Giaimo BD; Schwarz P; Soller K; Vas V; Bartkuhn M; Blätte TJ; Döhner K; Bullinger L; Borggrefe T; Geiger H; Oswald F
    Leukemia; 2017 Nov; 31(11):2491-2502. PubMed ID: 28360416
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pontin is a critical regulator for AML1-ETO-induced leukemia.
    Breig O; Bras S; Martinez Soria N; Osman D; Heidenreich O; Haenlin M; Waltzer L
    Leukemia; 2014 Jun; 28(6):1271-9. PubMed ID: 24342949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Definition of a small core transcriptional circuit regulated by AML1-ETO.
    Stengel KR; Ellis JD; Spielman CL; Bomber ML; Hiebert SW
    Mol Cell; 2021 Feb; 81(3):530-545.e5. PubMed ID: 33382982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic Silencing of Eyes Absent 4 Gene by Acute Myeloid Leukemia 1-Eight-twenty-one Oncoprotein Contributes to Leukemogenesis in t(8;21) Acute Myeloid Leukemia.
    Huang S; Jiang MM; Chen GF; Qian K; Gao HH; Guan W; Shi JL; Liu AQ; Liu J; Wang BH; Li YH; Yu L
    Chin Med J (Engl); 2016 Jun; 129(11):1355-62. PubMed ID: 27231175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of the NHR4 domain structure in AML1-ETO abrogates SON binding and promotes leukemogenesis.
    Ahn EY; Yan M; Malakhova OA; Lo MC; Boyapati A; Ommen HB; Hines R; Hokland P; Zhang DE
    Proc Natl Acad Sci U S A; 2008 Nov; 105(44):17103-8. PubMed ID: 18952841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEIS2 Is an Oncogenic Partner in AML1-ETO-Positive AML.
    Vegi NM; Klappacher J; Oswald F; Mulaw MA; Mandoli A; Thiel VN; Bamezai S; Feder K; Martens JHA; Rawat VPS; Mandal T; Quintanilla-Martinez L; Spiekermann K; Hiddemann W; Döhner K; Döhner H; Stunnenberg HG; Feuring-Buske M; Buske C
    Cell Rep; 2016 Jul; 16(2):498-507. PubMed ID: 27346355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genome-wide studies identify a novel interplay between AML1 and AML1/ETO in t(8;21) acute myeloid leukemia.
    Li Y; Wang H; Wang X; Jin W; Tan Y; Fang H; Chen S; Chen Z; Wang K
    Blood; 2016 Jan; 127(2):233-42. PubMed ID: 26546158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.